Novartis and Johnson & Johnson to deprive Europeans of their right to Health

Novartis-Logo (1)

It was the last day of January that the European Commission decided to send a formal complaint against two pharmaceutical giants, Johnson and Johnson and Novartis, over an illegal secret deal that made European cancer patients suffer while it brought huge profits to the American and Swiss multinational accordingly.

After the meticulous research of DG Competition, that as usually, took around 10 years to bear fruit, it has been uncovered that the two of the three biggest Pharmaceutical companies of the world according to Forbes, were having a small party in Netherlands between 2005 and 2006 at the expense of the Dutch cancer patient. According to DG Comp, what was happening back then is that the Dutch branch of Johnson & Johnson in the Netherlands, Janssen-Cilag, had in its payroll for one year and a half a competitive pharmaceutical company specialized in generics called Sandoz. The latter is a proper known unit of the Swiss company Novartis. So, basically, Johnson and Johnson were paying to Novartis a huge amount of money for 17 months. Isn’t that weird? Competitor companies are supposed to have endless board meetings on how to steal money from each other and not sharing bribes. Was 2005 the year that the management of the two powerful companies lost their minds due to burnout?

The Pay for Delay Deal

Well, think again! These people knew very well what they were doing. We are talking here about the anticompetitive bad practice of Pharmaceuticals called “Pay for Delay” where one brand name is bribing the generic drug competitor in order to delay the release of the cheaper generic drug in the market. In our case the generic drug that was deliberately and illegally delayed to launch in the Dutch market is Fentanyl and it is a drug that is mainly used by cancer patients to relieve pain. In a nutshell, these two companies deprived the Dutch cancer patients from the right to be able to buy a much cheaper drug, so that they can save millions of Euros by preventing a market share loss that a cheaper substitute product in the market would bring.

On the antitrust statement of DG Competition on the 31st of January, Mr. Almunia, the EU Competition Commissioner, said: “If our preliminary conclusions are confirmed, the Dutch subsidiaries of Johnson & Johnson and Novartis entered into a so-called “co-promotion” agreement to avoid competing against each other, depriving users of fentanyl in the Netherlands from access to a cheaper pain killer,”… “The commission is determined to fight undue delays in the market entry of generic medicines so that European citizens have access to affordable health care”. The Basque EU Commissioner says it here very well, but he certainly cannot say anything to the Dutch patients that were not given the alternative of cheap Fentanyl for 17 monhts! Can he?

DG Comp is doing Fundraising

Unfortunately, it seems that this antitrust statement can serve only in two things: a) make impression and b) make the Commission richer. If the Commission wins this battle with the pharmaceutical dinosaurs, which we all hope it will, the only benefit will be a few billion Euros for DG Comp. And of course we live in crisis and Mr. Almunia needs to play the role of the Fundraiser but in the end of the day this will not solve the Pay for Delay syndrome that is expanding like a plague in Europe and is menacing significantly public health. I mean, what is 7 billion euros for Johnson and Johnson to pay as fine compared to the millions or billions that the company has probably saved by exercising this anticompetitive covert technique? And of course, we are talking here about one case that goes back 10 years ago and was uncovered now. Who knows how many other similar incidents we had or we have at this moment in Europe happening at the expense of the European citizen, which will never see the light of publicity? Hence, the culminant question here is: What next? How can the European citizen be sure that this kind of corporate bribing will not be repeated in the future?

The European Parliament had an idea

Only a week after the antitrust statement, a new draft law was voted on the 6th of February in the European Parliament that seems relevant to the topic of this story. The basic concept behind that is that European patients should be able to buy cheaper generic medicines. This is an excellent concept. The European Sting and all Europeans welcome this spirit from the European law makers without a doubt. However, the European Parliament only voted in favour of some new deadlines and transparency standards on pricing and reimbursement of generic medicines. As usually, all this will be addressed to the 27 member states.

Of course, this is something that Europe needed to have anyway, because the rules that are now in action and describe these procedures are almost 25 years old (1989). It is true that the procedures were poorly defined and slow while, as Mrs. Antoniya Parvanova, rapporteur from the Alliance of Liberals and Democrats for Europe (ALDE), said, sometimes it took a country up to 700 days to make decisions on pricing and reimbursement of medicines. However, why was this matter brought up in the European Parliament now and not before? Is it to take the next step after Mr. Almunia’s antitrust statement?

I am afraid not. The reasons are twofold:

a)      This vote apparently is not going to stop Pharmaceuticals to pay for delay

b)      The draft law was voted on the 6th of February, when on the 4th was the World Cancer Day. The period that the draft law was voted was a period with numerous events aiming at cancer awareness all around the world. Is it a coincidence that the flash addicted European Parliament voted for this in the beginning of February and not in March?

Overall the draft law is a good reform addressed to member states to improve the European health system as a whole but let’s be honest here. Big Pharmaceuticals will be still free out there to sign golden deals under the table with generic competitors, in order to delay the launch of their product so that they keep the prices and profits high for themselves. Who will touch these people? Or better who can touch these people? Is a few billion fine enough to make them stop?

I guess not. The only cure from this cancer is that the patient, the European citizen, is aware of what exactly is happening behind her back and I hope that with this story the Sting has contributed to that.

the sting Milestone

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Multilateralism’s ‘proven record of service’ is focus of first-ever International Day

Property regimes for international couples in Europe: new rules apply in 18 Member States as of today

Why Eurozone can afford spending for growth

The refugee crisis brings to light EU’s most horrible flaws and nightmares

It’s time to disrupt Human Resources if we want talent fit for the digital age

EU commits €9 million in humanitarian aid for the most vulnerable families in Myanmar

The 10 most common types of plastic choking Europe’s rivers

A digital tax sounds like a great idea. Here’s why it might not be universally popular

Island nations on climate crisis frontline ‘not sitting idly by’

The European Green Deal sets out how to make Europe the first climate-neutral continent by 2050, boosting the economy, improving people’s health and quality of life, caring for nature, and leaving no one behind

Facility for Refugees in Turkey: €127 million to boost EU’s largest ever humanitarian programme

Nearly three million more displaced year-on-year, warns refugee agency chief, but solutions are within reach

Ten reasons to be optimistic in 2019

THE COMMITTEES: From the colonies to the space race – past, present, future converge in Fourth Committee

Why Sweden’s cashless society is no longer a utopia

Light at the end of the Eurozone tunnel

Conflict diamonds and climate change: Cooperate, don’t compete over natural resources urges Guterres

Syria’s Idlib ‘on the brink’ of a nightmare, humanitarian chiefs warn, launching global solidarity campaign

Commission deepens criticism on German economic policies

Mobile 360 Africa 11-13 July 2017

Human rights breaches in Bangladesh, Cuba and Vietnam

European Parliament marks EU accession prospects for Serbia and Kosovo

Eurozone dignitaries play with people’s life savings

These are the world’s healthiest nations

Vegans in France are using extreme tactics to stop people eating meat

Youth leaders share positive visions of the future, as Guterres launches UN75 in New York

The new assembly lines: Why AI needs low-skilled workers too

Africa-Europe Alliance: first projects kicked off just three months after launch

5 reasons why biodiversity matters – to human health, the economy and your wellbeing

July was the hottest month ever – what does that actually mean?

Six children among 53 confirmed fatalities after Libya detention centre airstrikes: Security Council condemns attack

Future EU farm policy: Agriculture MEPs urge fair funding, no renationalisation

Joint UN-Red Cross appeal to end rising sexual violence as a weapon of war

How fungi could save the world

This tool shows you which cities will flood as ice sheets melt

Antitrust: Commission publishes study on the application of Interchange Fees Regulation

28 million elective surgeries may be cancelled worldwide: how non-COVID-19 medical care is suffering

Greece will probably stay in the Eurozone but at what cost?

UN allocates $20 million in emergency funding, as Cyclone Idai disaster unfolds

A day in the life of a Venezuelan migrant in Boa Vista, Brazil

Competition: The European Commission launches a process to address the issue of collective bargaining for the self-employed

Don’t take African generosity towards refugees for granted, says UN refugee chief

We need to measure innovation better. Here’s how

The most unlikely innovators are changing ICT for development – it’s time we took notice

The UK option: An overarching alternative for the whole Brexit options

Tackling youth unemployment through the eyes of a European entrepreneur

2014 budget: The EU may prove unable to agree on own resources

Iran protests: Live ammunition reportedly used, says UN human rights office

Brexit uncertainty keeps shaking the world’s financial markets

Coldplay stop touring to save the world: is pop music going sustainable?

JADE Spring Meeting Live Coverage: Entrepreneurial skills in the digital markets

Rohingya refugee shelters ‘washed away’ in Bangladesh monsoon rains: UN agency

Ursula von der Leyen: ‘We must not hold onto yesterday’s economy as we rebuild’

The end of Spitzenkandidat: EU leaders concluded unexpectedly on EU top jobs

UN recorded 64 new allegations of sexual exploitation or abuse in the past three months

Turkish and Greek Cypriot leaders ready for talks with UN chief on improved relations

Storms and snow in Lebanon worsen plight for Syrian refugees

COVID-19: How leaders can create a new and better normal

The Internet of Bodies is here. This is how it could change our lives.

Two out of every five American couples now meet online

More Stings?

Advertising

Comments

  1. I believe this is one of the so much important information for me.
    And i’m satisfied studying your article. But wanna
    remark on few basic things, The site style is perfect, the articles is in point of fact excellent : D.
    Just right task, cheers

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s